Dette gælder for alle fem kræfttyper (brystkræft, ikke - småcellet lungekræft, prostatakræft, kirtelkræft i maven og kræft i hoved - og halsregionen).
The addition of TAXOTERE to other anticancer treatments produced significant increases in response rates, disease progression or survival in all five types of cancer (breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer).